Trial Outcomes & Findings for The Predictive Value of Ureteral Jet Assessment With Ultrasound in Patients Presenting With Acute Renal Colic (NCT NCT02577146)
NCT ID: NCT02577146
Last Updated: 2019-12-10
Results Overview
Number of days that have elapsed from date of diagnosis to date of stone passage or intervention to maximum observation time (42 days).
COMPLETED
NA
74 participants
42 days
2019-12-10
Participant Flow
Participant milestones
| Measure |
Study Ultrasound
Study ultrasound with ureteral jet assessment will be obtained after CT diagnosis of ureteral calculus is made. Ureteral jet data will be documented and patients will be followed prospectively for 42 days for spontaneous stone passage or need for surgical intervention.
renal and bladder ultrasound with ureteral jet assessment: The number of jets from each ureteral orifice will be tabulated over time so that ureteral jet frequency, defined as number of jets per minute, can be calculated. Patients will be categorized into three groups. Group I- no ureteral jets on the symptomatic side; Group II- continuous low-level ureteral jet on the symptomatic side; Group III- ureteral jets similar to nonsymptomatic side.
|
|---|---|
|
Overall Study
STARTED
|
74
|
|
Overall Study
COMPLETED
|
46
|
|
Overall Study
NOT COMPLETED
|
28
|
Reasons for withdrawal
| Measure |
Study Ultrasound
Study ultrasound with ureteral jet assessment will be obtained after CT diagnosis of ureteral calculus is made. Ureteral jet data will be documented and patients will be followed prospectively for 42 days for spontaneous stone passage or need for surgical intervention.
renal and bladder ultrasound with ureteral jet assessment: The number of jets from each ureteral orifice will be tabulated over time so that ureteral jet frequency, defined as number of jets per minute, can be calculated. Patients will be categorized into three groups. Group I- no ureteral jets on the symptomatic side; Group II- continuous low-level ureteral jet on the symptomatic side; Group III- ureteral jets similar to nonsymptomatic side.
|
|---|---|
|
Overall Study
Lost to Follow-up
|
8
|
|
Overall Study
Physician Decision
|
3
|
|
Overall Study
Screen Failure
|
17
|
Baseline Characteristics
Race and Ethnicity were not collected from any participant.
Baseline characteristics by cohort
| Measure |
Study Ultrasound
n=46 Participants
Study ultrasound with ureteral jet assessment will be obtained after CT diagnosis of ureteral calculus is made. Ureteral jet data will be documented and patients will be followed prospectively for 42 days for spontaneous stone passage or need for surgical intervention.
renal and bladder ultrasound with ureteral jet assessment: The number of jets from each ureteral orifice will be tabulated over time so that ureteral jet frequency, defined as number of jets per minute, can be calculated. Patients will be categorized into three groups. Group I- no ureteral jets on the symptomatic side; Group II- continuous low-level ureteral jet on the symptomatic side; Group III- ureteral jets similar to nonsymptomatic side.
|
|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=46 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
43 Participants
n=46 Participants
|
|
Age, Categorical
>=65 years
|
3 Participants
n=46 Participants
|
|
Age, Continuous
|
45.1 years
STANDARD_DEVIATION 13.9 • n=46 Participants
|
|
Sex: Female, Male
Female
|
16 Participants
n=46 Participants
|
|
Sex: Female, Male
Male
|
30 Participants
n=46 Participants
|
|
Region of Enrollment
United States
|
46 Participants
n=46 Participants
|
PRIMARY outcome
Timeframe: 42 daysPopulation: 28 cases were not included in analysis due to screen failures, subject non-compliance and missing data.
Number of days that have elapsed from date of diagnosis to date of stone passage or intervention to maximum observation time (42 days).
Outcome measures
| Measure |
Study Ultrasound
n=46 Participants
Study ultrasound with ureteral jet assessment will be obtained after CT diagnosis of ureteral calculus is made. Ureteral jet data will be documented and patients will be followed prospectively for 42 days for spontaneous stone passage or need for surgical intervention.
renal and bladder ultrasound with ureteral jet assessment: The number of jets from each ureteral orifice will be tabulated over time so that ureteral jet frequency, defined as number of jets per minute, can be calculated. Patients will be categorized into three groups. Group I- no ureteral jets on the symptomatic side; Group II- continuous low-level ureteral jet on the symptomatic side; Group III- ureteral jets similar to nonsymptomatic side.
|
|---|---|
|
Time in Days From Diagnosis to Stone Passage.
Present Jets
|
5 Days
Interval 3.0 to 13.0
|
|
Time in Days From Diagnosis to Stone Passage.
Absent Jets
|
13 Days
Interval 8.0 to
Sample size is too small to estimate upper limit of 95% confidence interval.
|
SECONDARY outcome
Timeframe: 42 daysPopulation: 28 cases were not included in analysis due to screen failures, subject non-compliance and missing data.
Outcome measures
| Measure |
Study Ultrasound
n=46 Participants
Study ultrasound with ureteral jet assessment will be obtained after CT diagnosis of ureteral calculus is made. Ureteral jet data will be documented and patients will be followed prospectively for 42 days for spontaneous stone passage or need for surgical intervention.
renal and bladder ultrasound with ureteral jet assessment: The number of jets from each ureteral orifice will be tabulated over time so that ureteral jet frequency, defined as number of jets per minute, can be calculated. Patients will be categorized into three groups. Group I- no ureteral jets on the symptomatic side; Group II- continuous low-level ureteral jet on the symptomatic side; Group III- ureteral jets similar to nonsymptomatic side.
|
|---|---|
|
The Number of Cases With Concordant Treatment Recommendations Based on the Ultrasound and CT Scan.
|
29 Cases
|
Adverse Events
Study Ultrasound
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Alana Desai, M.D.
Washington University School of Medicine
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place